Table 3.

Patient and tumour characteristics of metabolomics

	TFC (n = 18)	PCa (n = 21)	CRPC (n = 13)
Age(years)
Median (range)	56 (37–80)	74 (58–82)	74 (46–88)
Baseline PSA (ng/mL)
Median (range)	3.389 (0.41–14.7)	33.64 (6.66–284)	83.33 (22.86–101)
Post-treatment PSA (ng/ml)
Median (range)			0.955 (0.01–37.33)
Gleason score, n (%)
≤ 6		4 (19.05%)	1 (7.69%)
7		7 (33.33%)	1 (7.69%)
≥ 8		3 (14.29%)	3 (23.08%)
Local treatment, n (%)
Radical Prostatectomy		6 (28.57%)
Endocrinotherapy		9 (42.86%)